VEGFA and neoplasm: DMS-TACE avoids the systemic vascular endothelial growth factor (VEGF) response, which may facilitate tumor growth and metastatic seeding [24,25], associated with cTACE and DEB-TACE [26], and spares the smaller vessels, reducing the risk of ischemia-reperfusion injury [27].